Referencias: 1. BRIVIACT® (brivaracetam). Información para prescribir. 2. Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015 Dec;56(12):1890-8. 3. Baulac M et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2017 Jan;16(1):43-54. 4. Elsho- JP, Cawello W, Andreas JO, Mathy FX, Braun M. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson’s disease and restless legs syndrome. Drugs. 2015 Apr;75(5):487-501. 5. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol. 2003 Dec;60(12):1721-8. 6. Truong D et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010 Jun;16(5):316-23. 7. Misra VP, Colosimo C, Charles D, Chung TM, Maisonobe P, Om S; INTEREST IN CD2 study group. INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin. J Neurol. 2018 Feb;265(2):402-409. 8. Novotna A et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011 Sep;18(9):1122-31. 9. Oreja-Guevara C. Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity. Expert Rev Neurother. 2012 Apr;12(4 Suppl):3-8. 10. EPAR, Assessment report for Circadin. Procedure No. EMEA/H/C/695.